Investigation of the Relation Between FAS, FASLG Polymorphisms and Serum Fas, FasL Levels in Patients with Psoriasis

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2: ii18-ii23. DOI: 10.1136/ard.2004.03321710.1136/ard.2004.033217Open DOISearch in Google Scholar

2. Erkek E. Psoriazis Etyopatogenezi. Turkiye Klinikleri J Dermatol-Special Topics. 2008;1(3):1-14.Search in Google Scholar

3. Roman II, Orasan MS, Coneac A, Marina EM, Pop AD, Orasan RI. Genetic and Hormonal Determinations in a Pair of Identical Twins with Early Onset Psoriasis Vulgaris: Case Report and a Brief Review of the Literature. Rev Romana Med Lab. 2017; 25(3):287-94 DOI: 10.1515/rrlm-2017-002110.1515/rrlm-2017-0021Open DOISearch in Google Scholar

4. Oskay T, Erdem C. Apopitoz ve Dermatolojideki Önemi. Turkiye Klinikleri J Dermatol. 2000;10(3):213-21.Search in Google Scholar

5. Ada S. Psoriazis Sistemik Bir Hastalık mıdır? Turkiye Klinikleri J Dermatol-Special Topics. 2008;1(3):45-8.Search in Google Scholar

6. Oskay T, KundakçI N. Psoriasisde genetik bulgular. Turkiye Klinikleri J Dermatol. 2000;10(2):139-45.Search in Google Scholar

7. Asgari R, Yari K, Mansouri K, Bakhtiari M. Association analysis of FAS -670 A/G and FASL -844 C/T polymorphisms with risk of generalized agressive periodontitis disease. Biomed Rep. 2018;8 (4): 391-395.Search in Google Scholar

8. Ozdemirkiran FG, Nalbantoglu S, Gokgoz Z, Payzin BK, Vural F, Cagiran S, Berdeli A. FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. Arch Med Sci. 2017;13(2): 426-432. DOI: 10.5114/aoms.2015.5396310.5114/aoms.2015.53963Search in Google Scholar

9. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ull-mann Y, Kalish RS. Fas pulls the trigger on psoriasis. Am J Pathol. 2006;168(1):170-5. DOI: 10.2353/aj-path.2006.04135410.2353/aj-path.2006.041354Open DOISearch in Google Scholar

10. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305-8. DOI: 10.1126/science.281.5381.130510.1126/science.281.5381.1305Search in Google Scholar

11. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-46. DOI: 10.1016/0092-8674(95)90013-610.1016/0092-8674(95)90013-6Open DOISearch in Google Scholar

12. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34(8-9):577-82. DOI: 10.1016/S0161-5890(97)00081-310.1016/S0161-5890(97)00081-3Open DOISearch in Google Scholar

13. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183-8.Search in Google Scholar

14. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132-8. DOI: 10.4049/jimmunol.170.1.13210.4049/jimmunol.170.1.13212496392Search in Google Scholar

15. Seishima M, Seishima M, Takemura M, Saito K, Kitajima Y. Increased serum soluble Fas, tumor necrosis factor alpha and interleukin 6 concentrations in generalized pustular psoriasis. Dermatology. 1998;196(3):371-2.Search in Google Scholar

16. Mysliwiec H, Baran A, Mysliwiec P, Gorska M, Flisiak I. Upregulation of the sFas/sFasL system in psoriatic patients. Add Med Sci. 2015;60(1):64-8. DOI: 10.1016/j.advms.2014.10.00510.1016/j.advms.2014.10.00525437350Search in Google Scholar

17. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327-30.Search in Google Scholar

18. Xia B, Yu YH, Guo QS, Li XY, Jiang L, Li J. Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol. 2005;11(3):415-7. DOI: 10.3748/wjg.v11.i3.41510.3748/wjg.v11.i3.415420535115637757Open DOISearch in Google Scholar

19. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL–844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202(7):967-74. DOI: 10.1084/jem.2005070710.1084/jem.20050707Open DOISearch in Google Scholar

20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. DOI: 10.1093/nar/16.3.121510.1093/nar/16.3.1215Open DOISearch in Google Scholar

21. Ozel EG, Duran GG, Celik MM, Duran N, Gunesacar R. Fas and Fas ligand gene polymophisims in Turkish patient with Familial Mediterranean Fever. Gene. 2017; 623:29-32. DOI: 10.1016/j.gene.2017.04.03710.1016/j.gene.2017.04.037Open DOISearch in Google Scholar

22. Ghoreschi K, Mrowietz U, Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med. 2003;81(8):471-80. DOI: 10.1007/s00109-003-0460-910.1007/s00109-003-0460-9Open DOISearch in Google Scholar

23. Allombert-Blaise C, Tamiji S, Mortier L, Fauvel H, Tual M, Delaporte E, et al. Terminal differentiation of human epidermal keratinocytes involves mitochondria- and caspase-dependent cell death pathway. Cell Death Differ. 2003;10(7):850-2. DOI: 10.1038/sj.cdd.440124510.1038/sj.cdd.4401245Open DOISearch in Google Scholar

24. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal. 2003;15(11):983-92. DOI: 10.1016/S0898-6568(03)00093-710.1016/S0898-6568(03)00093-7Open DOISearch in Google Scholar

25. Alenzi FQ. The role of apoptotic proteins in patients with systemic lupus erythematosis. Egypt J Immunol. 2009;16(1):107-16.Search in Google Scholar

26. Islam Z, Jahan I, Ahammad RU, Shahnaij M, Nahar S, Mohammad QD. FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Banladeshi patients with Guillain-Barre syndrome. Plos One. 2018;12;13(2): e0192703.10.1371/journal.pone.0192703580904629432441Search in Google Scholar

27. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69(4):415-29.Search in Google Scholar

28. Kim K-M, Lee K, Hong Y-S, Park H-Y. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med. 2000;32(4):246. DOI: 10.1038/emm.2000.4110.1038/emm.2000.4111190279Open DOISearch in Google Scholar

29. Asgari R, Mansouri K, Bakhtiari M, Bidmeshkipour A, Yari K, Zadeh FS, Raygani AV. Association of FAS -670 A/G and FASL -844 C/T polymorphisms with idiopathic azospermia in Wertern Iran. Eur J Obstet Gynecol Reprod Biol. 2017; 218: 55-59. DOI: 10.1016/j.ejogrb.2017.09.00310.1016/j.ejogrb.2017.09.00328942044Open DOISearch in Google Scholar

30. Park JY, Lee W-K, Jung D-K, Choi J-E, Park T-I, Lee E-B, et al. Polymorphisms in the FAS and FASL Genes and Survival of Early Stage Non–small Cell Lung Cancer. Clin Cancer Res. 2009;15(5):1794-800. DOI: 10.1158/1078-0432.CCR-08-177010.1158/1078-0432.CCR-08-177019240174Open DOISearch in Google Scholar